Overview

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat patients with mild to moderate Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
TauRx Therapeutics Ltd
Treatments:
Cholinesterase Inhibitors